New York, NY -- May 16, 2019 -- InvestorsHub NewsWire -- via NextBigtTcker.com
 

 


Zevotek, Inc. (USOTC: ZVTK) is rated OVERALL BULLISH today by Stock Technical Analysis (stockta.com/ZVTK).  Yesterday the company unveiled a software as a service (SaaS) solution for the $85 billion SaaS B2B market that it has kept under wraps for the last year.  Today the company announced plans to release a detailed presentation on the SaaS solution next week on Thursday, May 23rd, 2019.  An opportunity exits to accumulate ZVTK now in the $0.30 to $0.40 range for a potential double when the news on the SaaS solution comes out next week.

ZVTK PPS Double Potential From $0.30 Accumulation

ZVTK is an old company and until recently, an almost completely dormant company with less than $500,000 in total trading volume in the last five years.  It’s a tight float play in the $0.30 range with less than 10 million shares issued and out.  The weighted average share price is $0.36.  With a 52-week high of $0.70, ZVTK has the very credible potential to deliver a double from here.

“Over a year ago, ZVTK entered into a strategic relationship with a start-up software firm developing a key software as a service (SaaS) solution designed to revolutionize the B2B marketplace.  Over the course of the 2018 calendar year, that strategic relationship evolved to include ZVTK taking a major equity stake in the SaaS start-up.  Now ZVTK is preparing to bring the SaaS solution to market.  Gardner predicts the SaaS market in 2019 will reach $85 billion and grow to over $113 billion by 2021.  Management plans to soon reveal the details of the SaaS solution for the B2B marketplace.”


Next Big Ticker has recently covered other stocks making news to include Generex Biotechnology (GNBT), North American Cannabis Holding, Inc. (PURA) and Kali-Extracts (KALY). 

For further information visit  www.zevotek.io.

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Generex Biotechnology (CE) Charts.
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Generex Biotechnology (CE) Charts.